Fig 1: ROC curves of renalase and evaluated biomarkers for the prediction of ischemia in the HFrEF phenotype. The curves should be interpreted with regard to Table 5. AUCs: BNP (0.980), galectin-3 (0.747), sST2 (0.788), renalase (0.814), syndecan-1 (0.801), cystatin C (0.749), GDF-15 (0.731). ROC, receiver operating characteristic; AUC, area under the curve; BNP, brain natriuretic peptide; sST2, soluble source of tumorigenicity 2; GDF-15, growth differentiation factor 15.
Fig 2: ROC curves of renalase and evaluated biomarkers for the prediction of ischemia in the total heart failure group. The curves should be interpreted with regard to Table 4. AUCs: BNP (0.837), sST2 (0.712), renalase (0.753), galectin-3 (0.726), syndecan-1 (0.709), cystatin C (0.704), GDF-15 (0.735). ROC, receiver operating characteristic; AUC, area under the curve; BNP, brain natriuretic peptide; sST2, soluble source of tumorigenicity 2; GDF-15, growth differentiation factor 15.
Fig 3: Echocardiography and cardiac remodeling. (A) Representative echocardiography in the three groups; LVIDd and LVIDs are shown in white lines. (B) Representative Masson’s trichrome in the ventricle of each group. The collagen fibers were stained in blue. (C) Quantitative analysis of Masson’s trichrome in each group. (D) and (E) Serum NE and BNP concentrations in each group. (F) and (G) %LVEF and %LVFS in each group. (H) and (I) LVIDs and LVIDd in each group. (J) and (K) LVPWs and LVPWd in each group. * p < 0.05 vs. the control group, ** p < 0.01 vs. the control group. # p < 0.05 vs. the METH group, ## p < 0.01 vs. the METH group. METH, methamphetamine; DAPA, dapagliflozin; LVEF, left ventricular ejection fraction; LVFS, left ventricular fraction shortening; LVIDd, left ventricular internal diameter at end-diastole; LVIDs, left ventricular internal diameter at end-systolic; LVPWd, left ventricular posterior wall thickness at end diastole; LVPWs, left ventricular posterior wall thickness at end systole; NE, noradrenaline; BNP, B-type natriuretic peptide.
Fig 4: Characteristics of groups divided according to NPPB expression levels in The Cancer Genome Atlas‐mesothelioma (TCGA‐MESO) cohort. (A) Oncoprint showing the genetic alterations of the patients in TCGA‐MESO cohort with high and low NPPB expression. Color differences indicate different types of genetic alterations. (B–D) Dot plots showing the correlation between NPPB and CLDN15 (B), VIM (C), or CLDN15/VIM (D) (C/V) gene expression values in TCGA‐MESO cohort data. Red lines represent regression lines. (E, F) Kaplan–Meier curves of overall survival (E) and progression‐free survival (F) in NPPB High and NPPB Low groups.
Supplier Page from Abcam for Human BNP ELISA Kit